Hemiasterlin-derived payloads disrupt the scaffolding used in cell division. One is carried by the experimental antibody drug luveltamab tazevibulin.
Luveltamab tazevibulin, or STRO-002, uses the folate receptor alpha antibody to deliver the tubulin-targeting hemiasterlin derivative SC209. SC239 is the linker-warhead used to assemble the conjugate, not a synonym for the released SC209 alone. The primary discovery study reported antigen-dependent killing, bystander activity and efficacy in xenograft models. This is a different scaffold within the tubulin class, not a mechanism unrelated to tubulin.
Showing the molecule this term concerns: Luveltamab tazevibulin.
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/